RxDoctor Payments Data

Rocky Fowler, MD

Family Medicine · Harrisonburg, VANPI 1952568156

Payments from drug & device makers

$1,887in general payments, 2019–2025

Across 112 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$479
  • Lilly USA, LLC$370
  • Novo Nordisk$222
  • Biohaven Pharmaceutical Holding Company Ltd.$191
  • Smith+Nephew$140
  • Pfizer$113
  • plus $371 from 10 others

What the payments were for

  • Food & beverage$1,85498%
  • Education$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,887 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$147,095
Medicare patients
326
Services billed
1,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$107,656
EliquisApixaban69$68,171
MounjaroTirzepatide43$57,936
JardianceEmpagliflozin39$44,613
XareltoRivaroxaban20$25,231
JanuviaSitagliptin Phosphate17$24,980
VraylarCariprazine Hcl15$21,564
Breo ElliptaFluticasone/Vilanterol18$7,001
SymbicortBudesonide/Formoterol Fumarate15$5,191
LantusInsulin Glargine,hum.Rec.Anlog16$3,146
Pregabalin50$2,997
Losartan Potassium214$2,348
Divalproex Sodium ErDivalproex Sodium17$2,331
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,176
Levothyroxine Sodium178$1,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$222$107,65690 claims
PfizerEliquis, Paxlovid$113$69,60181 claims
Lilly USA, LLCMounjaro$370$57,93643 claims
Johnson & JohnsonXarelto$83$25,23120 claims
AbbVieVraylar$479$21,56415 claims
AstraZenecaSymbicort$75$5,19115 claims
Sanofi-aventis U.S. LLCLantus$17$3,14616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Harrisonburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →